Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 8
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (178)
- Volume 15, 2024 (6)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 8, 2017
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, Ferraù F
Lung Cancer: Targets and Therapy 2017, 8:259-269
Published Date: 14 December 2017
Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2017, 8:249-257
Published Date: 8 December 2017
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2017, 8:241-247
Published Date: 6 December 2017
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
Wojcik E, Kulpa JK
Lung Cancer: Targets and Therapy 2017, 8:231-240
Published Date: 28 November 2017
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M
Lung Cancer: Targets and Therapy 2017, 8:217-229
Published Date: 6 November 2017
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
Lung Cancer: Targets and Therapy 2017, 8:207-216
Published Date: 30 October 2017
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T
Lung Cancer: Targets and Therapy 2017, 8:191-206
Published Date: 24 October 2017
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS
Lung Cancer: Targets and Therapy 2017, 8:179-190
Published Date: 19 October 2017
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Jain RK, Chen H
Lung Cancer: Targets and Therapy 2017, 8:169-177
Published Date: 13 October 2017
Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer – significance and development
Cascone R, Carlucci A, Pierdiluca M, Santini M, Fiorelli A
Lung Cancer: Targets and Therapy 2017, 8:161-167
Published Date: 10 October 2017
EGFR T790M: revealing the secrets of a gatekeeper
Ko B, Paucar D, Halmos B
Lung Cancer: Targets and Therapy 2017, 8:147-159
Published Date: 9 October 2017
Proton beam therapy in non-small cell lung cancer: state of the art
Harada H, Murayama S
Lung Cancer: Targets and Therapy 2017, 8:141-145
Published Date: 23 August 2017
Clinical staging of malignant pleural mesothelioma: current perspectives
Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL
Lung Cancer: Targets and Therapy 2017, 8:127-139
Published Date: 18 August 2017
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R
Lung Cancer: Targets and Therapy 2017, 8:109-125
Published Date: 18 August 2017
Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges
Spyratos D, Papadaki E, Lampaki S, Kontakiotis T
Lung Cancer: Targets and Therapy 2017, 8:101-107
Published Date: 7 August 2017
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
Niki M, Yokoi T, Kurata T, Nomura S
Lung Cancer: Targets and Therapy 2017, 8:91-99
Published Date: 3 August 2017
Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being
Lehto RH
Lung Cancer: Targets and Therapy 2017, 8:79-90
Published Date: 28 July 2017
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Seetharamu N, Preeshagul IR, Sullivan KM
Lung Cancer: Targets and Therapy 2017, 8:67-78
Published Date: 13 July 2017
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M
Lung Cancer: Targets and Therapy 2017, 8:57-66
Published Date: 12 July 2017
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, Facchinetti F
Lung Cancer: Targets and Therapy 2017, 8:45-55
Published Date: 7 July 2017
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
Jamil MO, Jerome MS, Miley D, Selander KS, Robert F
Lung Cancer: Targets and Therapy 2017, 8:39-44
Published Date: 12 June 2017
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects
Nardi-Agmon I, Peled N
Lung Cancer: Targets and Therapy 2017, 8:31-38
Published Date: 17 May 2017
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2017, 8:21-30
Published Date: 22 February 2017
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
Thakur MK, Wozniak AJ
Lung Cancer: Targets and Therapy 2017, 8:13-19
Published Date: 13 February 2017
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
Somasundaram A, Burns TF
Lung Cancer: Targets and Therapy 2017, 8:1-11
Published Date: 11 January 2017